0001571049-17-007240.txt : 20170804 0001571049-17-007240.hdr.sgml : 20170804 20170804112701 ACCESSION NUMBER: 0001571049-17-007240 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARQULE INC CENTRAL INDEX KEY: 0001019695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043221586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21429 FILM NUMBER: 171007461 BUSINESS ADDRESS: STREET 1: ONE WALL STREET CITY: BURLINGTON STATE: MA ZIP: 01803 BUSINESS PHONE: 781-994-0300 MAIL ADDRESS: STREET 1: ONE WALL STREET CITY: BURLINGTON STATE: MA ZIP: 01803 10-Q 1 t1700460_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

Quarterly report pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the Quarter Ended June 30, 2017

Commission File No. 000-21429

ArQule, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		04-3221586
(State of Incorporation)		(I.R.S. Employer Identification Number)

One Wall Street, Burlington, Massachusetts 01803

(Address of Principal Executive Offices)

(781) 994-0300

(Registrant’s Telephone Number, including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405) of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨		Accelerated filer x
Non-accelerated filer ¨		Smaller reporting company ¨
(Do not check if a smaller reporting company)		Emerging growth company ¨

Indicate If an emerging growth company, indicate by check by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ¨ No x

Number of shares outstanding of the registrant’s Common Stock as of July 20, 2017:

Common Stock, par value $.01 71,171,551 shares outstanding

ARQULE, INC.

QUARTER ENDED JUNE 30, 2017

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

Item 1. — Unaudited Condensed Financial Statements

	Condensed Balance Sheets (Unaudited) June 30, 2017 and December 31, 2016	3

	Condensed Statements of Operations and Comprehensive Loss (Unaudited) three and six months ended June 30, 2017 and 2016	4

	Condensed Statements of Cash Flows (Unaudited) six months ended June 30, 2017 and 2016	5

	Notes to Unaudited Condensed Financial Statements	6

Item 2. — Management’s Discussion and Analysis of Financial Condition and Results of Operations		14

Item 3. — Quantitative and Qualitative Disclosures about Market Risk		20

Item 4. — Controls and Procedures		21

PART II - OTHER INFORMATION		21

Item 1. — Legal Proceedings		21

Item 1A. — Risk Factors		21

Item 2. — Unregistered Sales of Equity Securities and Use of Proceeds		21

Item 3. — Defaults Upon Senior Securities		21

Item 4. — Mine Safety Disclosures		21

Item 5. — Other Information		21

Item 6. — Exhibits		21

SIGNATURES		22

ARQULE, INC.

CONDENSED BALANCE SHEETS (Unaudited)

	June 30, 2017			December 31, 2016
	(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
ASSETS
Current assets:
Cash and cash equivalents	$	16,899		$	15,267
Marketable securities-short term		14,108			15,859
Prepaid expenses and other current assets		421			822
Total current assets		31,428			31,948

Property and equipment, net		142			180
Other assets		204			252
Total assets	$	31,774		$	32,380

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses	$	7,261		$	8,700
Total current liabilities		7,261			8,700

Long-term liabilities:
Notes payable		14,427			—
Total liabilities		21,688			8,700

Commitment and contingencies

Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding					—
Common stock, $0.01 par value; 100,000,000 shares authorized; 71,171,551 and 71,146,209 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively		711			711
Additional paid-in capital		528,994			527,802
Accumulated other comprehensive income (loss)		(7	)		2
Accumulated deficit		(519,612	)		(504,835	)
Total stockholders’ equity		10,086			23,680
Total liabilities and stockholders’ equity	$	31,774		$	32,380

The accompanying notes are an integral part of these interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)

	THREE MONTHS ENDED June 30,						SIX MONTHS ENDED June 30,
	2017			2016			2017			2016
	(IN THOUSANDS, EXCEPT PER SHARE DATA)

Research and development revenue	$	—		$	1,072		$	—		$	2,299

Costs and expenses:
Research and development		4,983			4,337			10,177			8,535
General and administrative		1,866			1,887			3,940			3,931
Total costs and expenses		6,849			6,224			14,117			12,466

Loss from operations		(6,849	)		(5,152	)		(14,117	)		(10,167	)

Interest income		37			52			59			86
Interest expense		(389	)		—			(719	)		—

Net loss		(7,201	)		(5,100	)		(14,777	)		(10,081	)

Unrealized gain (loss) on marketable securities		(5	)		—			(9	)		29
Comprehensive loss	$	(7,206	)	$	(5,100	)	$	(14,786	)	$	(10,052	)

Basic and diluted net loss per share:
Net loss per share	$	(0.10	)	$	(0.07	)	$	(0.21	)	$	(0.15	)

Weighted average basic and diluted common shares outstanding		71,149			71,062			71,143			68,275

The accompanying notes are an integral part of these interim unaudited financial statements.

ARQULE, INC.

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

	SIX MONTHS ENDED JUNE 30,
	2017			2016
	(IN THOUSANDS)
Cash flows from operating activities:
Net loss	$	(14,777	)	$	(10,081	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		38			53
Amortization of premium (discount) on marketable securities		(9	)		40
Amortization of debt discount		150			—
Non-cash stock compensation		828			1,015
Changes in operating assets and liabilities:
Prepaid expenses and other assets		449			294
Accounts payable and accrued expenses		(1,439	)		1
Deferred revenue		—			(2,290	)
Net cash used in operating activities		(14,760	)		(10,968	)
Cash flows from investing activities:
Purchases of marketable securities		(14,076	)		(21,648	)
Proceeds from sale or maturity of marketable securities		15,827			20,765
Additions to property and equipment		—			(15	)
Net cash provided by (used in) investing activities		1,751			(898	)
Cash flows from financing activities:
Proceeds from notes payable and warrants, net		14,624			—
Proceeds from stock offering, net		—			15,174
Proceeds from employee stock option exercises and employee stock purchase plan purchases		17			163
Net cash provided by financing activities		14,641			15,337
Net increase in cash and cash equivalents		1,632			3,471
Cash and cash equivalents, beginning of period		15,267			13,983
Cash and cash equivalents, end of period	$	16,899		$	17,454

The accompanying notes are an integral part of these interim unaudited financial statements.

ARQULE, INC.

NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These drugs target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine.

ArQule has a long history of kinase drug discovery and development, having discovered and introduced nine kinase inhibitors into clinical trials. Our drug discovery efforts have been informed by our historical expertise in chemistry, our work in rational drug design and by our insight into kinase binding and regulation. We have applied this knowledge to produce significant chemical matter for a number of kinase targets and to build an extensive library of proprietary compounds with the potential to target multiple kinases in oncology and other therapeutic areas, such as rare diseases. We expect to bring further preclinical programs forward and to interrogate our library against new targets beyond kinases either directly or with collaborators.

Our proprietary pipeline of product candidates is directed toward molecular targets and biological processes with demonstrated roles in the development of both human cancers and rare, non-oncology diseases. All of these programs are being developed in targeted, biomarker-defined patient populations. By seeking out subgroups of patients that are most likely to respond to our drugs, we intend to identify small, often orphan, indications that allow for focused and efficient development. At the same time, in addition to pursuing these potentially fast-to-market strategies, we also pursue development in other indications that could allow us to expand the utility of the drugs if approved. The pipeline includes the following wholly-owned compounds:

•

ARQ 087, a multi-kinase inhibitor designed to preferentially inhibit the FGFR family of kinases, in Phase 2 for intrahepatic cholangiocarcinoma (iCCA) and in Phase 1b for multiple oncology indications;

•

ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in Phase1/2 in rare Overgrowth Disease and in Phase 1 for multiple oncology indications and in the rare disease, Proteus syndrome, in partnership with the National Institutes of Health (NIH);

•

ARQ 751, a next-generation inhibitor of AKT, in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation;

•

ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in a Phase 1 for B-cell malignancies refractory to other therapeutic options; and

•

ARQ 761, a ß-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell death, in Phase 1/2 in multiple oncology indications in partnership with The University of Texas Southwest Medical Center.

Our most advanced partnered asset was tivantinib (ARQ 197), an orally administered, small molecule inhibitor of the c-Met receptor tyrosine kinase (“MET”) and its biological pathway. We licensed commercial rights to tivantinib for human cancer indications to Daiichi Sankyo Co., Ltd. (“Daiichi Sankyo”) in the U.S., Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where we have licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”).

Our METIV-HCC trial was a pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single-agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Daiichi Sankyo and us. The primary endpoint was overall survival (OS) in the intent-to-treat (ITT) population, and the secondary endpoint was progression-free survival (PFS) in the same population. On February 17, 2017, we and Daiichi Sankyo announced that the METIV-HCC trial did not meet its primary endpoint of improving OS.

Our JET-HCC trial was a second pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single-agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Kyowa Hakko Kirin. The primary endpoint was PFS. On March 27, 2017, we reported that our partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan and that the trial did not meet its primary endpoint of improving PFS.

Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. In the six months ended June 30, 2017 and 2016, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $14.8 million and $11.0 million, respectively.

Our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, our ability to enter into additional corporate collaborations and the terms of such collaborations, results of research and development, unanticipated required capital expenditures, competitive and technological advances, acquisitions and other factors. We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product. On January 6, 2017, we entered into a loan and security agreement (the “Loan Agreement”) with a principal balance of $15 million (see Note 8). The terms of the Loan Agreement require payments of interest on a monthly basis through September 2018 and payments of interest and principal from October 2018 to August 2021. We anticipate that our cash, cash equivalents and marketable securities on hand at June 30, 2017, which includes the funds received on January 6, 2017 from our Loan Agreement will be sufficient to finance our operations for at least 12 months from the issuance date of these financial statements. We expect that we will need to raise additional capital or incur indebtedness to continue to fund our operations in the future. Our ability to raise additional funds will depend on financial, economic and market conditions, and due to global capital and credit market conditions or for other reasons, we may be unable to raise capital when needed, or on terms favorable to us. If necessary funds are not available, we may have to delay, reduce the scope of, or eliminate some of our development programs, potentially delaying the time to market for any of our product candidates.

We have prepared the accompanying condensed financial statements pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to these rules and regulations. These condensed financial statements should be read in conjunction with our audited financial statements and footnotes related thereto for the year ended December 31, 2016 included in our annual report on Form 10-K filed with the SEC on March 9, 2017.

In our opinion, the accompanying unaudited condensed financial statements contain all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of its financial position as of June 30, 2017, and its results of operations and cash flows for the three months ended June 30, 2017 and June 30, 2016. The results of operations for such interim periods are not necessarily indicative of the results to be achieved for the full year. The condensed balance sheet at December 31, 2016, was derived from audited annual financial statements, but does not contain all of the footnote disclosures from the annual financial statements

2. COLLABORATIONS AND ALLIANCES

Daiichi Sankyo Tivantinib Agreement

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we shared development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. In each quarter the tivantinib collaboration costs we incurred were compared with those of Daiichi Sankyo. If our costs for the quarter exceeded Daiichi Sankyo’s, we recognized revenue on the amounts due to us under the contingency adjusted performance model. Revenue was calculated on a pro-rata basis using the time elapsed from inception of the agreement over the estimated duration of the development period under the agreement. If our costs for the quarter were less than those of Daiichi Sankyo, we reported the amount due to Daiichi Sankyo as contra-revenue in that quarter. To the extent that our share of Phase 3 collaboration costs exceeded the amount of milestones and royalties received, that excess was netted against milestones and royalties earned and was not reported as contra-revenue.

Our cumulative share of the Daiichi Sankyo Phase 3 costs through June 30, 2017 totaled $108.8 million. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through June 30, 2017 by $68.8 million which are not required to be repaid upon expiration of the agreement.

Revenue for this agreement was recognized using the contingency-adjusted performance model with an estimated development period through December 31, 2016. On February 17, 2017, we and Daiichi Sankyo announced that the METIV-HCC trial did not meet its primary end point of improving OS. As a result, we do not anticipate receiving further royalties or milestones in connection with the agreement.

For the three months and six months ended June 30, 2017, zero was recognized as revenue. For the three months and six months ended June 30, 2016, $0.6 million and $1.4 million, respectively, were recognized as revenue.

Kyowa Hakko Kirin Licensing Agreement

As previously reported, on April 27, 2007, we entered into an exclusive license agreement with Kyowa Hakko Kirin to develop and commercialize tivantinib in Japan and parts of Asia. Revenue for this agreement was recognized using the contingency-adjusted performance model with an estimated development period through December 31, 2016. On March 27, 2017, we reported that our partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of improving PFS. As a result, we do not anticipate receiving further royalties or milestones in connection with the agreement.

For the three months and six months ended June 30, 2017, zero were recognized as net revenue. For the three months and six months ended June 30, 2016, $0.5 million and $0.9 million, respectively, were recognized as revenue.

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.

We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.

We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).

For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.

Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

The following is a summary of the fair value of available-for-sale marketable securities we held at June 30, 2017 and

December 31, 2016:

June 30, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	14,115	$	-	$	(7	)	$	14,108
Total available-for-sale marketable securities	$	14,115	$	-	$	(7	)	$	14,108

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	15,857	$	7	$	(5	)	$	15,859
Total available-for-sale marketable securities	$	15,857	$	7	$	(5	)	$	15,859

Our available-for-sale marketable securities in a loss position at June 30, 2017, and December 31, 2016 were in a continuous unrealized loss position for less than 12 months.

The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:

	June 30, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	14,176	$	14,176	$	—	$	—
Corporate debt securities-short term		14,108		—		14,108		—
Total	$	28,284	$	14,176	$	14,108	$	—

	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	12,923	$	12,923	$	—	$	—
Corporate debt securities-short term		15,859		—		15,859		—
Total	$	28,782	$	12,923	$	15,859	$	—

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31, 2016
Accounts payable	$	988	$	710
Accrued payroll		1,109		1,856
Accrued outsourced pre-clinical and clinical fees		4,455		5,461
Accrued professional fees		413		363
Other accrued expenses		296		310
	$	7,261	$	8,700

5. NET LOSS PER SHARE

Net loss per share is computed using the weighted average number of common shares outstanding. Basic and diluted net loss per share amounts are equivalent for the periods presented as the inclusion of potential common shares in the number of shares used for the diluted computation would be anti-dilutive to loss per share. Potential common shares, for the three and six months ended June 30, 2017, include 10,773,443 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options and 354,330 shares that would be issued upon the exercise of the warrants issued in conjunction with our January 6, 2017 loan agreement. Potential common shares, for the three and six months ended June 30, 2016, include 9,189,198 shares that would be issued upon the exercise of outstanding employee and Board of Director stock options.

6. STOCK-BASED COMPENSATION AND STOCK PLANS

Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the three months ended June 30, 2017 and 2016.

The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development	$	74	$	109	$	204	$	299
General and administrative		212		312		625		716
Total stock-based compensation expense	$	286	$	421	$	829	$	1,015

In the three and six months ended June 30, 2017 and 2016, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.

Option activity under our stock plans for the six months ended June 30, 2017 was as follows:

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016		8,715,048		$	3.71
Granted		2,537,500			1.19
Exercised		—			—
Cancelled		(479,105	)		4.96
Outstanding as of June 30, 2017		10,773,443		$	3.06

Exercisable as of June 30, 2017		6,484,316		$	4.16

In April 2017, the Company amended its chief executive officer’s (the “CEO’s”) employment agreement to grant the CEO a maximum of 600,000 performance-based stock options that vest upon the achievement of certain performance and market based targets. In April 2017, the Company amended its chief operating officer’s (the “COO’s”) employment agreement to grant the COO 300,000 performance-based stock units that vest upon the achievement of certain performance and market based targets. In April 2017, the Company amended its chief medical officer’s (the “CMO’s”) employment agreement to grant the CMO 260,000 performance-based stock options that vest upon the achievement of certain performance based targets. In April 2017, certain other employees were granted a total of 270,000 performance-based stock options that vest upon the achievement of certain performance based targets. Through June 30, 2017 no expense has been recorded for any performance-based stock options granted to the CEO, COO, CMO, or to any other employees.

The aggregate intrinsic value of options outstanding at June 30, 2017 was $496 and $37 related to exercisable options. The weighted average fair value of options granted in the six months ended June 30, 2017 and 2016 was $0.72 and $1.10 per share, respectively. No options were exercised in the six months ended June 30, 2017.

Shares vested, expected to vest and exercisable at June 30, 2017 are as follows:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at June 30, 2017		10,566,460	$	3.06		6.2	$	479
Exercisable at June 30, 2017		6,484,316	$	4.16		4.3	$	37

The total compensation cost not yet recognized as of June 30, 2017 related to non-vested option awards was $2.7 million, which will be recognized over a weighted-average period of 3.3 years. During the three months ended June 30, 2017, 325,149 shares expired and 153,956 shares were forfeited. The weighted average remaining contractual life for options exercisable at June 30, 2017 was 4.3 years.

7. STOCK OFFERING

On February 26, 2016, we entered into definitive stock purchase agreements with certain institutional and accredited investors. In conjunction with this stock offering we issued 8,027,900 shares of our common stock and non-transferable options for 3,567,956 shares of our common stock for aggregate net proceeds of $15.2 million. Each option was exercisable for $2.50 per share and they all expired on March 22, 2017.

8. LOAN AGREEMENT

On January 6, 2017, Oxford Finance LLC, as collateral agent and a lender (the “Lender”), and any additional lenders that may become parties thereto, entered into a loan and security agreement with us (the “Loan Agreement”).

Pursuant to the terms of the Loan Agreement, the Lender issued us a loan in the principal amount of $15.0 million. The loan will bear interest at the rate equal to (a) the greater of (i) the 30 day U.S. LIBOR rate reported in the Wall Street Journal on the date occurring on the last business day of the month that immediately precedes the month in which the interest will accrue or (ii) 0.65% (b) plus 6.85%. The applicable interest rate on the loan at June 30, 2017 was 8.08%. We will have interest-only payments for 18 months, followed by an amortization period of 36 months. The maturity date of the loan is July 1, 2021.

The expected remaining repayment of the $15 million loan principal is as follows:

2018	$	1,667
2019		5,000
2020		5,000
2021		3,333
	$	15,000

Upon the earlier of prepayment or the maturity date, we will pay to the Lender a final payment of 6% of the full principal amount of the loan. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.

We paid the Lender an upfront facility fee of $75,000.

Pursuant to the terms of the Loan Agreement, we are bound by certain affirmative covenants setting forth actions that are required during the term of the Loan Agreement, including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent, including, without limitation, incurring certain additional indebtedness, entering into certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. We are in compliance with the loan covenants at June 30, 2017.

Upon the occurrence of an event of default under the Loan Agreement (subject to cure periods for certain events of default), all amounts owed by us thereunder will begin to bear interest at a rate that is 5% higher than the rate that is otherwise applicable and may be declared immediately due and payable by the Lender. Events of default under the Loan Agreement include, among other things, the following: the occurrence of certain bankruptcy events; the failure to make payments under the Loan Agreement when due; the occurrence of a material adverse change in our business, operations or financial condition ; the rendering of certain types of fines or judgments against us; any breach by us of any covenant (subject to cure for certain covenants only) made in the Loan Agreement; and the failure of any representation or warranty made by us in connection with the Loan Agreement to be correct in all material respects when made.

We have granted Lender, a security interest in substantially all of our personal property, rights and assets, other than intellectual property, to secure the payment of all amounts owed to the Lender under the Loan Agreement. We have also agreed not to encumber any of our intellectual property without required lenders’ prior written consent.

In connection with entering into the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of 354,330 shares of our common stock (the “Lender Warrants”). The warrants are exercisable immediately, have a per-share exercise price of $1.27 and have a term of ten years. We have recorded the relative fair value of the warrants as a discount to the carrying value of the notes payable with a corresponding increase to additional paid in capital.

9. RECENT ACCOUNTING PRONOUNCEMENTS

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.

In May 2017 the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. This new standard provides clarity and reduces both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation-Stock Compensation, to a change to the terms or conditions of a share-based payment award. This new standard will be effective for us on January 1, 2018, however early adoption is permitted. As of June 30, 2017, the adoption of this standard is not expected to have a material impact on our financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The new standard involves several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. We adopted this ASU in 2017 and it will not have a material impact on our financial position, results of operations or statement of cash flows.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The new standard requires that all lessees recognize the assets and liabilities that arise from leases on the balance sheet and disclose qualitative and quantitative information about its leasing arrangements. The new standard will be effective for us on January 1, 2019. We are currently evaluating the potential impact that this standard may have on our financial position and results of operations.

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customer Topic 606s, Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers Topic 606, Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing implementation guidance. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers Topic 606, Narrow-Scope Improvements and Practical Expedients, related to disclosures of remaining performance obligations, as well as other amendments to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers. In December 2016, the FASB issued ASU No. 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amends certain narrow aspects of the guidance issued in ASU 2014-09, “Revenue from Contracts with Customers” (Topic 606). ASU 2014-09 superseded all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. We evaluated this ASU and determined that it will not have a material impact on our financial position or results of operations.

10. INCOME TAXES

As of December 31, 2016, we had federal NOL, state NOL, and research and development credit carryforwards of approximately $382,781, $202,137 and $27,779 respectively, which expire at various dates through 2036. Approximately $15,080 of our federal NOL and $929 of our state NOL were generated from excess tax deductions from share-based awards.

The Company adopted ASU No. 2016-09 in the first quarter of 2017. The recognition of the excess tax benefits from share-based payments mentioned above increased deferred tax assets and retained earnings accordingly. As the company doesn’t expect taxable income in the foreseeable future, we reserved the full amount at the time of the recognition and there was no impact on the net positions of deferred tax assets and retained earnings. The amount of excess tax benefits or deficiencies will fluctuate from period to period based on the price of our stock, the volume of share-based instruments settled or vested, and the value assigned to employee equity awards under U.S. GAAP and these fluctuations did not affect our net deferred tax position in the first six months of 2017.

At June 30, 2017 and December 31, 2016, we had no unrecognized tax benefits. We do not expect that the total amount of unrecognized tax benefits will significantly increase in the next twelve months. Our policy is to recognize interest and penalties related to uncertain tax positions in income tax expense. As of June 30, 2017 and December 31, 2016, we had no accrued interest or penalties related to uncertain tax positions. Our U.S. federal tax returns for the tax years 2013 through 2016 and our state tax returns for the tax years 2013 through 2016 remain open to examination. Prior tax years remain open to the extent of net operating loss and tax credit carryforwards.

Utilization of NOL and research and development credit carryforwards may be subject to a substantial annual limitation in the event of an ownership change that has occurred previously or could occur in the future pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, as well as similar state provisions. An ownership change may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income, and may, in turn, result in the expiration of a portion of those carryforwards before utilization. In general, an ownership change, as defined by Section 382, results from transactions that increase the ownership of certain stockholders or public groups in the stock of a corporation by more than 50 percentage points over a three year period. We undertook a detailed study of our NOL and research and development credit carryforwards through January 31, 2017, to determine whether such amounts are likely to be limited by Sections 382 or 383. As a result of this analysis, we currently do not believe any Sections 382 or 383 limitations will significantly impact our ability to offset income with available NOL and research and development credit carryforwards. However, future ownership changes under Section 382 may limit our ability to fully utilize these tax benefits.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion should be read in conjunction with our condensed financial statements and accompanying notes contained in this quarterly report on Form 10-Q and our audited financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016.

•

ARQ 092, a selective inhibitor of the AKT serine/threonine kinase, in Phase 1 for multiple oncology indications and in the rare disease, Proteus syndrome, in partnership with the National Institutes of Health (NIH);

•

ARQ 751, a next-generation inhibitor of AKT, in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation;

•

ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, planned to advance to Phase 1 by Q3 2017; and

•

Our METIV-HCC trial was a pivotal Phase 3 randomized, double-blind, controlled study of tivantinib as single agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Daiichi Sankyo and us. The primary endpoint was overall survival (OS) in the intent-to-treat (ITT) population, and the secondary endpoint was progression-free survival (PFS) in the same population. On February 17, 2017, we and Daiichi Sankyo announced that the METIV-HCC trial did not meet its primary endpoint of improving.

Our JET-HCC was a pivotal Phase 3, randomized, double-blind, controlled study of tivantinib as single-agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC conducted by Kyowa Hakko Kirin in Japan. On March 27, 2017, we reported that our partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of improving PFS.

We have incurred a cumulative deficit of approximately $520 million from inception through June 30, 2017. We recorded a net loss for 2015 and 2016 and expect a net loss for 2017.

As previously reported, on December 18, 2008, we entered into a license, co-development and co-commercialization agreement with Daiichi Sankyo to conduct research, clinical trials and the commercialization of tivantinib in human cancer indications in the U.S., Europe, South America and the rest of the world, excluding Japan, China (including Hong Kong), South Korea and Taiwan, where Kyowa Hakko Kirin has exclusive rights for development and commercialization. On February 17, 2017, we and Daiichi Sankyo announced that the MET-IV-HCC trial did not meet its primary end point of improving OS. As a result, we do not anticipate receiving further royalties or milestones in connection with the agreement.

LIQUIDITY AND CAPITAL RESOURCES

	June 30,		December 31,		Increase (decrease)
	2017		2016		$			%
	(in millions)
Cash, cash equivalents and marketable securities-short term	$	31.0	$	31.1		(0.1	)		-	%
Working capital		24.2		23.2		1.0			4.0	%

	Six Months Ended
	June 30, 2017			June 30, 2016			Increase (decrease)
	(in millions)
Cash flow from:
Operating activities	$	(14.8	)	$	(11.0	)	$	(3.8	)
Investing activities		1.8			(0.9	)		2.7
Financing activities		14.6			15.3			(0.7	)

Cash flow from operating activities. Our uses of cash for operating activities have primarily consisted of salaries and wages for our employees, facility and facility-related costs for our offices and laboratories, fees paid in connection with preclinical and clinical studies, laboratory supplies and materials, and professional fees. The sources of our cash flow from operating activities have consisted primarily of payments received from our collaborators for services performed or upfront payments for future services. For the six months ended June 30, 2017 and 2016, our net use of cash was primarily driven by payments for operating expenses which resulted in net cash outflows of $14.8 million and $11.0 million, respectively.

Cash flow from investing activities. Our net cash provided by investing activities of $1.8 million for the six months ended June 30, 2017, was comprised of net maturities of of marketable securities. Our net cash used by investing activities of $0.9 million for the six months ended June 30, 2016, was comprised primarily of net purchases of marketable securities. The composition and mix of cash, cash equivalents and marketable securities may change frequently as a result of our constant evaluation of conditions in financial markets, the maturity of specific investments, and our near term liquidity needs.

Cash flow from financing activities. Our net cash provided by financing activities of $14.6 million for the six months ended June 30, 2017, was principally comprised of the net proceeds from the loan and security agreement that we entered into on January 6, 2017. Our net cash provided by financing activities of $15.3 million for the six months ended June 30, 2016, was comprised of net proceeds from our February 26, 2016 stock offering of $15.2 million and $0.1 million from stock option exercises and employee stock plan purchases.

Our cash equivalents and marketable securities typically include U.S. Treasury bill funds, money market funds, commercial paper, and U.S. federal and state agency backed certificates that have investment grade ratings. Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.

On February 26, 2016 we entered into definitive stock purchase agreements with certain institutional and accredited investors. In conjunction with this stock offering we issued 8,027,900 shares of our common stock and non-transferable options for 3,567,956 shares of our common stock for aggregate net proceeds of $15.2 million. Each option was exercisable for $2.50 per share and they all expired on March 22, 2017.

On January 6, 2017, we entered into a loan and security agreement in the principal amount of $15.0 million. The loan will bear interest at a minimum of 7.6% per annum and the interest rate will float based upon the 30 day U.S. LIBOR rate. We will have interest-only payments for 18 months, followed by an amortization period of 36 months. The maturity date of the loan is July 1, 2021.

We anticipate that our cash, cash equivalents and marketable securities on hand at June 30, 2017 which includes the funds received on January 6, 2017 from our loan and security agreement mentioned above will be sufficient to finance our operations into the late third quarter of 2018 which is greater than 12 months from the issuance date of these financial statements.

Our contractual obligations were comprised of the following as of June 30, 2017 (in thousands):

	Payment due by period
Contractual Obligations	Total		Less than 1 year		1 - 3 years		3 - 5 years		More than 5 years
Notes payable	$	15,900	$	—	$	9,167	$	6,733	$	—
Operating lease obligations		1,535		534		1,001		—		—
Purchase obligations		4,455		4,455		—		—		—
Total	$	21,890	$	4,989	$	10,168	$	6,733	$	—

Purchase obligations are comprised primarily of outsourced preclinical and clinical trial expenses and payments to license certain intellectual property to support our research efforts.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For additional information, please see the discussion of our significant accounting policies in Note 2 to the Financial Statements included in our Annual Report for the fiscal year ended December 31, 2016 on Form 10-K filed with the SEC on March 9, 2017.

RESULTS OF OPERATIONS

The following are the results of operations for the three and six months ended June 30, 2017 and 2016:

Revenue

					Increase (decrease)
	2017		2016		$			%
	(in millions)
For the three months ended June 30:
Research and development revenue	$	—	$	1.1	$	(1.1	)		(100	)%

For the six months ended June 30:
Research and development revenue	$	—	$	2.3	$	(2.3	)		(100	)%

Research and development revenue in the three and six months ended June 30, 2017 was zero due to the end of the estimated development period on December 31, 2016 for both the Daiichi Sankyo tivantinib development agreement and the Kyowa Hakko Kirin exclusive license agreement. Research and development revenue in the three months ended June 30, 2016 revenue is comprised of revenue of $0.6 million from our Daiichi Sankyo METIV-HCC trial and $0.5 million from our Kyowa Hakko Kirin JET-HCC trial.

Research and development revenue in the six months ended June 30, 2016 revenue is comprised of revenue of $1.4 million from our Daiichi Sankyo METIV-HCC trial and $0.9 million from our Kyowa Hakko Kirin JET-HCC trial.

Research and development

					Increase (decrease)
	2017		2016		$		%
	(in millions)
For the three months ended June 30:
Research and development	$	5.0	$	4.3	$	0.7		15	%

For the six months ended June 30:
Research and development	$	10.2	$	8.5	$	1.7		19	%

Research and development expense in the quarter ended June 30, 2017 increased by $0.7 million primarily due to higher outsourced clinical and product development costs for our pipeline programs.

Research and development expense in the six months ended June 30, 2017 increased by $1.7 million primarily due to higher outsourced clinical and product development costs for our pipeline programs.

At June 30, 2017 and 2016 we had 19 and 21 employees dedicated to our research and development program, respectively.

Overview

Our research and development expense consists primarily of salaries and related expenses for personnel, costs of contract manufacturing services, costs of facilities and equipment, fees paid to professional service providers in conjunction with our clinical trials, fees paid to research organizations in conjunction with pre-clinical animal studies, costs of materials used in research and development, consulting, license, and sponsored research fees paid to third parties and depreciation of associated laboratory equipment. We expect that our research and development expense will remain significant as we continue to develop our portfolio of oncology programs.

We have not accumulated and tracked our internal historical research and development costs or our personnel and personnel-related costs on a program-by-program basis. Our employee and infrastructure resources are allocated across several projects, and many of our costs are directed to broadly applicable research endeavors. As a result, we cannot state the costs incurred for each of our oncology programs on a program-by-program basis.

The expenses incurred by us to third parties for pre-clinical and clinical trials in the current quarter and since inception of our tivantinib program were as follows (in millions):

Oncology program		Current status		Three Months Ended June 30, 2017				Program-to- date
Met program—Tivantinib		Phase 3		$	-			$	84.9

Under the terms of our tivantinib collaboration agreement with Daiichi Sankyo we shared development costs equally with our share of Phase 3 costs funded solely from milestones and royalties. Our cumulative share of Phase 3 collaboration costs has exceeded the amount of milestones received through June 30, 2017 by $68.8 million and is not reflected in the above table.

Our future research and development expenses in support of our current and future oncology programs will be subject to numerous uncertainties in timing and cost to completion. We test potential products in numerous pre-clinical studies for safety, toxicology, and efficacy. We may conduct multiple clinical trials for each product. As we obtain results from trials, we may elect to discontinue or delay clinical trials for certain products in order to focus our resources on more promising products. Completion of clinical trials may take several years or more, and the length of time generally varies substantially according to the type, complexity, novelty, and intended use of a product. It is not unusual for the pre-clinical and clinical development of each of these types of products to take nine years or more, and for total development costs to exceed $500 million for each product.

We estimate that clinical trials of the type generally needed to secure new drug approval are typically completed over the following timelines:

		Estimated Completion
Clinical Phase		Period
Phase 1		1 – 2 years
Phase 2		2 – 3 years
Phase 3		2 – 4 years

The duration and the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others, the following:

●

the number of clinical sites included in the trials;

●

the length of time required to enroll suitable patients;

●

the number of patients that ultimately participate in the trials;

●

the duration of patient follow-up to ensure the absence of long-term product-related adverse events; and

●

the efficacy and safety profile of the product.

An element of our business strategy is to pursue the research and development of a broad pipeline of products. This is intended to allow us to diversify the risks associated with our research and development expenditures. As a result, we believe our future capital requirements and future financial success do not substantially depend on any one product. To the extent we are unable to build and maintain a broad pipeline of products, our dependence on the success of one or a few products increases.

Our strategy includes entering into alliance arrangements with third parties to participate in the development and commercialization of our products, such as our collaboration agreements with Daiichi Sankyo and Kyowa Hakko Kirin. In the event that third parties have control over the clinical trial process for a product, the estimated completion date would be under control of that third party rather than under our control. We cannot forecast with any degree of certainty whether our products will be subject to future collaborative arrangements or how such arrangements would affect our development plans or capital requirements.

As a result of the uncertainties discussed above, we make significant estimates in determining the duration and completion costs of our oncology programs or when and to what extent we will receive cash inflows from the commercialization and sale of a product. Our inability to complete our oncology programs in a timely manner or our failure to enter into appropriate collaborative agreements could significantly increase our capital requirements and could adversely impact our liquidity. These uncertainties could force us to seek additional, external sources of financing from time-to-time in order to continue with our product development strategy. Our inability to raise additional capital, or to do so on terms reasonably acceptable to us, would jeopardize the future success of our business.

General and administrative

					Increase (decrease)
	2017		2016		$		%
	(in millions)
For the three months ended June 30:
General and administrative	$	1.9	$	1.9	$	-		-	%

For the six months ended June 30:
General and administrative	$	3.9	$	3.9	$	-		-	%

General and administrative expense remained constant in the three and six months ended June 30, 2017 compared with the comparable periods in 2016.

General and administrative headcount was 14 at June 30, 2017 and June 30, 2016.

Interest income and interest expense

					Increase (decrease)
	2017		2016		$			%
	(in thousands)
For the three months ended June 30:
Interest income	$	37	$	52	$	(15	)		(29	)%
Interest expense		389		—		389			100	%

For the six months ended June 30:
Interest income	$	59	$	86	$	(27	)		(31	)%
Interest expense		719		—		719			100	%

Interest income is derived from our portfolio of cash, cash equivalents and investments and decreased in the three and six month periods ended June 30, 2017 primarily due to a decrease in our portfolio balance. Interest expense is from the loan agreement we entered into on January 6, 2017

RECENT ACCOUNTING PRONOUNCEMENTS

For a discussion of new accounting pronouncements please read Note 9, Recent Accounting Pronouncements to our financial statements included in this report.

FORWARD LOOKING STATEMENTS

In addition to historical information, this report contains forward-looking statements. You can identify these forward-looking statements by their use of words such as “anticipate,” “assume,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “target,” “will” and other words and terms of similar meaning. You also can identify them by the fact that they do not relate strictly to historical or current facts. All statements which address operating performance, events or developments that the Company expects or anticipates will occur in the future, such as projections about its future results of operations, its financial condition, research, development and commercialization of its products and anticipated trends in its business are forward-looking statements.

In this report we make forward-looking statements regarding our drug development pipeline and our existing and planned clinical trials as well as projected financial results and our ability to fund operations with current cash, cash equivalents and marketable securities.

Drug development involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. For example, pre-clinical efforts associated with our product pipeline may fail or prove disappointing because our technology platform did not produce candidates with the desired characteristics. Animal xenograft pre-clinical studies may be unpredictive of human response. Positive information about early stage clinical trial results will not ensure that later stage or larger scale clinical trials will be successful.

Furthermore, our drugs may not demonstrate promising therapeutic effects; in addition, they may not demonstrate appropriate safety profiles in ongoing or later stage or larger scale clinical trials as a result of known or as yet unidentified side effects. The results achieved in later stage trials may not be sufficient to meet applicable regulatory standards. Problems or delays may arise during clinical trials or in the course of developing, testing or manufacturing our drugs that could lead us or our partner to discontinue development.

Even if later stage clinical trials are successful, the risk exists that unexpected concerns may arise from analysis of data or from additional data or that obstacles may arise or issues be identified in connection with review of clinical data with regulatory authorities or that regulatory authorities may disagree with our view of the data or require additional data or information or additional studies. Also, the planned timing of initiation of clinical trials and the duration and conclusion of such trials for our drugs are subject to the ability of the company to enroll patients, enter into agreements with clinical trial sites and investigators, and other technical hurdles and issues that may not be resolved.

We also make forward-looking statements regarding the adequacy of our financial resources. Our capital resources may not be adequate because our cash requirements may vary materially from those now planned depending upon the results of our drug discovery and development strategies, the outcomes of our clinical trials, our ability to enter into additional corporate collaborations in the future and the terms of such collaborations, results of research and development, the need for currently unanticipated capital expenditures, competitive and technological advances, acquisitions, financial market conditions and other factors. Additionally, our corporate collaborators may terminate their agreements with us, thereby eliminating that source of funding, because we may fail to satisfy the prescribed terms of the collaborations or for other reasons.

We cannot guarantee that we will be able to develop any of our drug candidates into a commercial product generating revenues. If we experience increased losses, we may have to seek additional financing from public and private sales of our securities, including equity securities. There can be no assurance that additional funding will be available when needed or on acceptable terms.

The factors, risks and uncertainties referred to above and others are more fully described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the SEC on February 28, 2017, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The forward-looking statements contained herein represent our judgment as of the date of this report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We own financial instruments that are sensitive to market risk as part of our investment portfolio. We have implemented policies regarding the amount and credit ratings of investments. Our investment portfolio is used to preserve our capital until it is used to fund operations, including our research and development activities. Our investments are evaluated quarterly to determine the fair value of the portfolio.

Our cash equivalents and marketable securities typically include commercial paper, money market funds, and U.S. Treasury bill funds that have investment grade ratings.

Our cash equivalents and our portfolio of marketable securities are subject to market risk due to changes in interest rates. Fixed rate interest securities may have their market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fall short of expectation due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates. Based on the type of securities we hold, we do not believe a change in interest rates would have a material impact on our financial statements. If interest rates were to increase or decrease by 1%, this would not result in a material change in the fair value of our investment portfolio.

ITEM 4. CONTROLS AND PROCEDURES

Our management, with the participation of our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2017. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2017, our Chief Executive Officer (Principal Executive Officer) and President and Chief Operating Officer (Principal Financial Officer) concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

There have been no changes in our internal control over financial reporting during the most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. — LEGAL PROCEEDINGS. None.

ITEM 1A. — RISK FACTORS. For information regarding factors that could affect our results of operations, financial condition and liquidity, see the risk factors discussion provided under “Risk Factors” in Item 1A of ArQule’s Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 9, 2017, as updated from time to time in our subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. See also, “Forward-Looking Statements” included in this Quarterly Report on Form 10-Q.

ITEM 2. — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. None.

ITEM 3. — DEFAULTS UPON SENIOR SECURITIES. None.

ITEM 4. — MINE SAFETY DISCLOSURES. Not applicable.

ITEM 5. — OTHERS INFORMATION. None.

ITEM 6. — EXHIBITS.

EXHIBIT NO.		DESCRIPTION
31.1		Rule 13a-14(a) Certificate of Chief Executive Officer, filed herewith.
31.2		Rule 13a-14(a) Certificate of Principal Financial Officer, filed herewith.
32		Rule 13a-14(b) Certificate of Chief Executive Officer and Chief Financial Officer, filed herewith.
101		Interactive Data File

ARQULE, INC.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ArQule, Inc.

Date: August 4, 2017	/s/ PETER S. LAWRENCE
	Peter S. Lawrence
	President and Chief Operating Officer
	(Principal Financial Officer)

	/s/ ROBERT J. WEISKOPF
	Robert J. Weiskopf
	Chief Financial Officer and Treasurer
	(Principal Accounting Officer)

EX-31.1 2 t1700460_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER

I, Paolo Pucci, certify that:

I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2017

	/s/ PAOLO PUCCI
	Paolo Pucci
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 t1700460_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATE OF THE PRINCIPAL FINANCIAL OFFICER

I, Peter S. Lawrence, certify that:

I have reviewed this quarterly report on Form 10-Q of ArQule, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2017

	/s/ PETER S. LAWRENCE
	Peter S. Lawrence
	President and Chief Operating Officer
	(Principal Financial Officer)

EX-32 4 t1700460_ex32.htm EXHIBIT 32

Exhibit 32

ARQULE, INC.

CERTIFICATE OF THE CHIEF EXECUTIVE OFFICER AND

PRINCIPAL FINANCIAL OFFICER

The undersigned, Paolo Pucci Chief Executive Officer (Principal Executive Officer) of ArQule, Inc. (the “Company”) and Peter S. Lawrence, President and Chief Operating Officer (Principal Financial Officer), of the Company, both duly elected and currently serving, hereby certify that, to the best of his or her knowledge:

the quarterly report on Form 10-Q for the period ending June 30, 2017, filed on behalf of the Company pursuant to the Securities Exchange Act of 1934 (the “Exchange Act”) and containing the financial statements of the Company, fully complies with the requirements of section 13(a) of the Exchange Act; and

the information contained in such quarterly report fairly presents, in all material respects, the financial condition and results of operations of the Company for the dates and periods covered by such quarterly report.

This certification accompanies the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the “2002 Act”) and shall not be deemed filed by the Company for purposes of Section 18 of the Exchange Act.

This certification is being made for the exclusive purpose of compliance by the Principal Executive Officer and Principal Financial Officer of the Company with the requirements of Section 906 of the 2002 Act, and may not be disclosed, distributed or used by any person for any reason other than as specifically required by law.

IN WITNESS WHEREOF, the undersigned have executed this Certificate as of the 4th day of August 2017.

/s/ PAOLO PUCCI
Name:	Paolo Pucci
Title:	Chief Executive Officer
	(Principal Executive Officer)

/s/ PETER S. LAWRENCE
Name:	Peter S. Lawrence
Title:	President and Chief Operating Officer
	(Principal Financial Officer)

EX-101.INS 5 arql-20170630.xml XBRL INSTANCE DOCUMENT 0001019695 2015-12-31 0001019695 arql:DefinitiveStockPurchaseAgreementsMember 2016-02-01 2016-02-26 0001019695 2016-04-01 2016-06-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2016-04-01 2016-06-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember arql:Phase3CollaborationCostsMember 2016-04-01 2016-06-30 0001019695 2016-01-01 2016-06-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2016-01-01 2016-06-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember arql:Phase3CollaborationCostsMember 2016-01-01 2016-06-30 0001019695 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001019695 2016-06-30 0001019695 us-gaap:DomesticCountryMember 2016-01-01 2016-12-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2016-01-01 2016-12-31 0001019695 2016-12-31 0001019695 us-gaap:EmployeeStockOptionMember 2016-12-31 0001019695 us-gaap:DomesticCountryMember 2016-12-31 0001019695 us-gaap:StateAndLocalJurisdictionMember 2016-12-31 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:CurrentMember 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2016-12-31 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2016-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 us-gaap:ResearchMember 2016-12-31 0001019695 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001019695 2017-01-06 0001019695 2017-01-01 2017-01-06 0001019695 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-04-30 0001019695 us-gaap:EmployeeStockOptionMember arql:ChiefExecutiveOfficerEmploymentAgreementMember us-gaap:ChiefExecutiveOfficerMember 2017-04-01 2017-04-30 0001019695 us-gaap:EmployeeStockOptionMember arql:ChiefMedicalOfficerEmploymentAgreementMember arql:ChiefMedicalOfficerMember 2017-04-01 2017-04-30 0001019695 us-gaap:PerformanceSharesMember arql:ChiefOperatingOfficerEmploymentAgreementMember us-gaap:ChiefOperatingOfficerMember 2017-04-01 2017-04-30 0001019695 2017-04-01 2017-06-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2017-04-01 2017-06-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember arql:Phase3CollaborationCostsMember 2017-04-01 2017-06-30 0001019695 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001019695 2017-01-01 2017-06-30 0001019695 arql:KyowaHakkoKirinLicensingAgreementMember 2017-01-01 2017-06-30 0001019695 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001019695 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001019695 arql:DaiichiSankyoTivantinibAgreementMember arql:Phase3CollaborationCostsMember 2017-01-01 2017-06-30 0001019695 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001019695 2017-06-30 0001019695 us-gaap:EmployeeStockOptionMember 2017-06-30 0001019695 us-gaap:CorporateDebtSecuritiesMember arql:CurrentMember 2017-06-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2017-06-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2017-06-30 0001019695 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2017-06-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001019695 arql:CurrentMember us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001019695 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001019695 2017-07-20 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure ARQULE INC 0001019695 arql --12-31 Accelerated Filer 71171551 10-Q 2017-06-30 false 2017 Q2

13983000

17454000

15267000

16899000

15859000

14108000

822000

421000

31948000

31428000

180000

142000

252000

204000

32380000

31774000

8700000

7261000

8700000

7261000

14427000

8700000

21688000

711000

527802000

528994000

2000

-7000

-504835000

-519612000

23680000

10086000

32380000

31774000

0.01

1000000

0.01

100000000

71146209

71171551

71146209

71171551

1072000 500000 600000 2299000 900000 1400000 0 0 0 0

4337000

8535000

4983000

10177000

1887000

3931000

1866000

3940000

6224000

12466000

6849000

14117000

-5152000

-10167000

-6849000

-14117000

52000

86000

37000

59000

389000

719000

-5100000

-10081000

-7201000

-14777000

29000

-5000

-9000

-5100000

-10052000

-7206000

-14786000

-0.07

-0.15

-0.10

-0.21

71062

68275

71149

71143

53000

38000

-40000

9000

150000

1015000

828000

-294000

-449000

1000

-1439000

-2290000

-10968000

-14760000

21648000

14076000

20765000

15827000

15000

-898000

1751000

14624000

15174000

163000

17000

15337000

14641000

3471000

1632000

<p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</b></p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">We generally classify our marketable securities as available-for-sale at the time of purchase and re-evaluate such designation as of each balance sheet date. Since we generally intend to convert them into cash as necessary to meet our liquidity requirements our marketable securities are classified as cash equivalents if the original maturity, from the date of purchase, is ninety days or less and as short-term investments if the original maturity, from the date of purchase, is in excess of ninety days but less than one year. Our marketable securities are classified as long-term investments if the maturity date is in excess of one year of the balance sheet date.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">We report available-for-sale investments at fair value as of each balance sheet date and include any unrealized gains and, to the extent deemed temporary, unrealized losses in stockholders’ equity. Realized gains and losses are determined using the specific identification method and are included in other income (expense) in the statement of operations and comprehensive loss.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">We conduct quarterly reviews to determine the fair value of our investment portfolio and to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. In the event that the cost basis of a security exceeds its fair value, we evaluate, among other factors, the duration of the period that, and extent to which, the fair value is less than cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, our intent to sell the investment and if it is more likely than not that we would be required to sell the investment before its anticipated recovery. Unrealized losses on available-for-sale securities that are determined to be temporary, and not related to credit loss, are recorded in accumulated other comprehensive income (loss).</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">For available-for-sale debt securities with unrealized losses, we perform an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security’s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in the statement of operations and comprehensive loss as an impairment loss.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following is a summary of the fair value of available-for-sale marketable securities we held at June 30, 2017 and</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">December 31, 2016:</p><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">June 30, 2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-style: italic;">Security type</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt; width: 603px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">14,115</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">-</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">(7</td><td style="text-align: left; padding-bottom: 2px; width: 15px;">)</td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">14,108</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,115</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">-</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(7</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">December 31, 2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-style: italic;">Security type</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt; width: 603px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">15,857</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 189px;">7</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">(5</td><td style="text-align: left; padding-bottom: 2px; width: 15px;">)</td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 188px;">15,859</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,857</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">7</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(5</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Our available-for-sale marketable securities in a loss position at June 30, 2017, and December 31, 2016 were in a continuous unrealized loss position for less than 12 months.</p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following tables present information about our assets that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. We value our level 2 investments using quoted prices for identical assets in the markets where they are traded, although such trades may not occur daily. These quoted prices are based on observable inputs, primarily interest rates. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. There were no transfers in or out of Level 1 or Level 2 measurements for the periods presented:</p><p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>June 30,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2017</b></p></td><td style="padding-bottom: 2px;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; width: 627px;">Cash equivalents</td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">14,176</td><td style="text-align: left; width: 16px;"> </td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">14,176</td><td style="text-align: left; width: 16px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">28,284</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,176</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; width: 627px;">Cash equivalents</td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">12,923</td><td style="text-align: left; width: 16px;"> </td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 189px;">12,923</td><td style="text-align: left; width: 16px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 188px;">—</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">28,782</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">12,923</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table>

<p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"><b>6. STOCK-BASED COMPENSATION AND STOCK PLANS</b></p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Our stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employees’ requisite service period (generally the vesting period of the equity grant). We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, expected option term, expected volatility of our stock over the option’s expected term, risk-free interest rate over the option’s expected term, and the expected annual dividend yield. We believe that the valuation technique and approach utilized to develop the underlying assumptions are appropriate in calculating the fair values of our stock options granted in the three months ended June 30, 2017 and 2016.</p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 80%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended<br />June 30,</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Six Months Ended<br />June 30,</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2016</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap">Research and development</td> <td> </td> <td style="text-align: left;" nowrap="nowrap">$</td> <td style="text-align: right;" nowrap="nowrap">74</td> <td> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap">$</td> <td style="text-align: right;" nowrap="nowrap">109</td> <td> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap">$</td> <td style="text-align: right;" nowrap="nowrap">204</td> <td> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap">$</td> <td style="text-align: right;" nowrap="nowrap">299</td> <td> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 8.65pt; width: 627px;">General and administrative</td> <td style="padding-bottom: 2px; width: 14px;"> </td> <td style="border-bottom: black 2px solid; text-align: left; width: 14px;"> </td> <td style="border-bottom: black 2px solid; text-align: right; width: 134px;">212</td> <td style="text-align: left; padding-bottom: 2px; width: 14px;"> </td> <td style="padding-bottom: 2px; width: 13px;"> </td> <td style="border-bottom: black 2px solid; text-align: left; width: 13px;"> </td> <td style="border-bottom: black 2px solid; text-align: right; width: 133px;">312</td> <td style="text-align: left; padding-bottom: 2px; width: 13px;"> </td> <td style="padding-bottom: 2px; width: 13px;"> </td> <td style="border-bottom: black 2px solid; text-align: left; width: 13px;"> </td> <td style="border-bottom: black 2px solid; text-align: right; width: 133px;">625</td> <td style="text-align: left; padding-bottom: 2px; width: 13px;"> </td> <td style="padding-bottom: 2px; width: 13px;"> </td> <td style="border-bottom: black 2px solid; text-align: left; width: 13px;"> </td> <td style="border-bottom: black 2px solid; text-align: right; width: 133px;">716</td> <td style="text-align: left; padding-bottom: 2px; width: 13px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 4px; text-indent: -8.65pt; padding-left: 17.3pt;">Total stock-based compensation expense</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">286</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">421</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">829</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">1,015</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In the three and six months ended June 30, 2017 and 2016, no stock-based compensation expense was capitalized and there were no recognized tax benefits associated with the stock-based compensation expense.</p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px 0pt 0.5in; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Option activity under our stock plans for the six months ended June 30, 2017 was as follows:</p> <p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">Stock Options</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Number of<br />Shares</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted<br />Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt; width: 1032px;">Outstanding as of December 31, 2016</td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;"> </td> <td style="text-align: right; width: 141px;">8,715,048</td> <td style="text-align: left; width: 14px;"> </td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 141px;">3.71</td> <td style="text-align: left; width: 14px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;">Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,537,500</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.19</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; text-indent: -8.65pt; padding-left: 8.65pt;">Cancelled</td> <td style="padding-bottom: 2px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(479,105</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">4.96</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 8.65pt;">Outstanding as of June 30, 2017</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">10,773,443</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">3.06</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;"> </td> <td> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable as of June 30, 2017</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">6,484,316</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4.16</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">In April 2017, the Company amended its chief executive officer’s (the “CEO’s”) employment agreement to grant the CEO a maximum of 600,000 performance-based stock options that vest upon the achievement of certain performance and market based targets. In April 2017, the Company amended its chief operating officer’s (the “COO’s”) employment agreement to grant the COO 300,000 performance-based stock units that vest upon the achievement of certain performance and market based targets. In April 2017, the Company amended its chief medical officer’s (the “CMO’s”) employment agreement to grant the CMO 260,000 performance-based stock options that vest upon the achievement of certain performance based targets. In April 2017, certain other employees were granted a total of 270,000 performance-based stock options that vest upon the achievement of certain performance based targets. Through June 30, 2017 no expense has been recorded for any performance-based stock options granted to the CEO, COO, CMO, or to any other employees.</p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The aggregate intrinsic value of options outstanding at June 30, 2017 was $496 and $37 related to exercisable options. The weighted average fair value of options granted in the six months ended June 30, 2017 and 2016 was $0.72 and $1.10 per share, respectively. No options were exercised in the six months ended June 30, 2017.</p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">Shares vested, expected to vest and exercisable at June 30, 2017 are as follows:</p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <table style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted-<br />Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in years)</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt; width: 615px;">Vested and unvested expected to vest at June 30, 2017</td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;"> </td> <td style="text-align: right; width: 189px;">10,566,460</td> <td style="text-align: left; width: 16px;"> </td> <td style="width: 16px;"> </td> <td style="text-align: left; width: 16px;">$</td> <td style="text-align: right; width: 189px;">3.06</td> <td style="text-align: left; width: 16px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;"> </td> <td style="text-align: right; width: 188px;">6.2</td> <td style="text-align: left; width: 15px;"> </td> <td style="width: 15px;"> </td> <td style="text-align: left; width: 15px;">$</td> <td style="text-align: right; width: 188px;">479</td> <td style="text-align: left; width: 15px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable at June 30, 2017</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,484,316</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">4.16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.3</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">37</td> <td style="text-align: left;"> </td> </tr> </table> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p> <p style="widows: 2; text-transform: none; text-indent: 20.15pt; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;">The total compensation cost not yet recognized as of June 30, 2017 related to non-vested option awards was $2.7 million, which will be recognized over a weighted-average period of 3.3 years. During the three months ended June 30, 2017, 325,149 shares expired and 153,956 shares were forfeited. The weighted average remaining contractual life for options exercisable at June 30, 2017 was 4.3 years.</p>

<table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">June 30, 2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-style: italic;">Security type</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt; width: 597px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 187px;">14,115</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 186px;">-</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 186px;">(7</td><td style="text-align: left; padding-bottom: 2px; width: 15px;">)</td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 186px;">14,108</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,115</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">-</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(7</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0px; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">December 31, 2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Amortized<br />Cost</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Gains</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Gross<br />Unrealized<br />Losses</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Fair<br />Value</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; font-style: italic;">Security type</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;"> </td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 17.3pt; width: 597px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 187px;">15,857</td><td style="text-align: left; padding-bottom: 2px; width: 16px;"> </td><td style="padding-bottom: 2px; width: 16px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 16px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 186px;">7</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 186px;">(5</td><td style="text-align: left; padding-bottom: 2px; width: 15px;">)</td><td style="padding-bottom: 2px; width: 15px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 15px;">$</td><td style="border-bottom: black 2px solid; text-align: right; width: 186px;">15,859</td><td style="text-align: left; padding-bottom: 2px; width: 15px;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px;">Total available-for-sale marketable securities</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,857</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">7</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">(5</td><td style="text-align: left; padding-bottom: 4px;">)</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table>

<table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: center;" colspan="2" nowrap="nowrap"><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>June 30,</b></p><p style="text-align: center; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; font-stretch: normal;"><b>2017</b></p></td><td style="padding-bottom: 2px;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; width: 621px;">Cash equivalents</td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 187px;">14,176</td><td style="text-align: left; width: 16px;"> </td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 186px;">14,176</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 186px;">—</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 186px;">—</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">28,284</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,176</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">14,108</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table><p style="widows: 2; text-transform: none; text-indent: 0.5in; margin: 0pt 0px; font: 10pt 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;"> </p><table style="widows: 2; text-transform: none; text-indent: 0px; width: 100%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;" nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Quoted<br />Prices in<br />Active<br />Markets<br />(Level 1)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Other<br />Observable<br />Inputs<br />(Level 2)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Significant<br />Unobservable<br />Inputs<br />(Level 3)</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; width: 621px;">Cash equivalents</td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 187px;">12,923</td><td style="text-align: left; width: 16px;"> </td><td style="width: 16px;"> </td><td style="text-align: left; width: 16px;">$</td><td style="text-align: right; width: 186px;">12,923</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 186px;">—</td><td style="text-align: left; width: 15px;"> </td><td style="width: 15px;"> </td><td style="text-align: left; width: 15px;">$</td><td style="text-align: right; width: 186px;">—</td><td style="text-align: left; width: 15px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Corporate debt securities-short term</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">—</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 34.55pt;">Total</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">28,782</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">12,923</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">15,859</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">—</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">June 30,<br />2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">December 31,<br />2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; width: 869px;">Accounts payable</td><td style="width: 13px;"> </td><td style="text-align: left; width: 13px;">$</td><td style="text-align: right; width: 149px;">988</td><td style="text-align: left; width: 12px;"> </td><td style="width: 12px;"> </td><td style="text-align: left; width: 12px;">$</td><td style="text-align: right; width: 148px;">710</td><td style="text-align: left; width: 12px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued payroll</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">1,109</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">1,856</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left;">Accrued outsourced pre-clinical and clinical fees</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">4,455</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">5,461</td><td style="text-align: left;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left;">Accrued professional fees</td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">413</td><td style="text-align: left;"> </td><td> </td><td style="text-align: left;"> </td><td style="text-align: right;">363</td><td style="text-align: left;"> </td></tr><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px;">Other accrued expenses</td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">296</td><td style="text-align: left; padding-bottom: 2px;"> </td><td style="padding-bottom: 2px;"> </td><td style="border-bottom: black 2px solid; text-align: left;"> </td><td style="border-bottom: black 2px solid; text-align: right;">310</td><td style="text-align: left; padding-bottom: 2px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">7,261</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">8,700</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table>

<table align="center" style="widows: 2; text-transform: none; text-indent: 0px; width: 80%; border-collapse: collapse; font: 10pt 'times new roman', times, serif; orphans: 2; letter-spacing: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended<br />June 30,</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Six Months Ended<br />June 30,</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2017</td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="padding-bottom: 2px; font-weight: bold;"> </td><td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2016</td><td style="padding-bottom: 2px; font-weight: bold;"> </td></tr><tr style="vertical-align: bottom;"><td nowrap="nowrap">Research and development</td><td> </td><td style="text-align: left;" nowrap="nowrap">$</td><td style="text-align: right;" nowrap="nowrap">74</td><td> </td><td> </td><td style="text-align: left;" nowrap="nowrap">$</td><td style="text-align: right;" nowrap="nowrap">109</td><td> </td><td> </td><td style="text-align: left;" nowrap="nowrap">$</td><td style="text-align: right;" nowrap="nowrap">204</td><td> </td><td> </td><td style="text-align: left;" nowrap="nowrap">$</td><td style="text-align: right;" nowrap="nowrap">299</td><td> </td></tr><tr style="background-color: transparent; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 2px; text-indent: -8.65pt; padding-left: 8.65pt; width: 621px;">General and administrative</td><td style="padding-bottom: 2px; width: 14px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 14px;"> </td><td style="border-bottom: black 2px solid; text-align: right; width: 132px;">212</td><td style="text-align: left; padding-bottom: 2px; width: 14px;"> </td><td style="padding-bottom: 2px; width: 14px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 13px;"> </td><td style="border-bottom: black 2px solid; text-align: right; width: 131px;">312</td><td style="text-align: left; padding-bottom: 2px; width: 13px;"> </td><td style="padding-bottom: 2px; width: 13px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 13px;"> </td><td style="border-bottom: black 2px solid; text-align: right; width: 131px;">625</td><td style="text-align: left; padding-bottom: 2px; width: 13px;"> </td><td style="padding-bottom: 2px; width: 13px;"> </td><td style="border-bottom: black 2px solid; text-align: left; width: 13px;"> </td><td style="border-bottom: black 2px solid; text-align: right; width: 131px;">716</td><td style="text-align: left; padding-bottom: 2px; width: 13px;"> </td></tr><tr style="background-color: white; vertical-align: bottom;"><td style="text-align: left; padding-bottom: 4px; text-indent: -8.65pt; padding-left: 17.3pt;">Total stock-based compensation expense</td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">286</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">421</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">829</td><td style="text-align: left; padding-bottom: 4px;"> </td><td style="padding-bottom: 4px;"> </td><td style="border-bottom: black 4px double; text-align: left;">$</td><td style="border-bottom: black 4px double; text-align: right;">1,015</td><td style="text-align: left; padding-bottom: 4px;"> </td></tr></table>

<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 90%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 2px solid; font-weight: bold;" nowrap="nowrap">Stock Options</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Number of<br />Shares</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="border-bottom: black 2px solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted<br />Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt; width: 1021px;">Outstanding as of December 31, 2016</td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;"> </td> <td style="text-align: right; width: 140px;">8,715,048</td> <td style="text-align: left; width: 14px;"> </td> <td style="width: 14px;"> </td> <td style="text-align: left; width: 14px;">$</td> <td style="text-align: right; width: 139px;">3.71</td> <td style="text-align: left; width: 13px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;">Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2,537,500</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1.19</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercised</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">—</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2px; text-indent: -8.65pt; padding-left: 8.65pt;">Cancelled</td> <td style="padding-bottom: 2px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">(479,105</td> <td style="text-align: left; padding-bottom: 2px;">)</td> <td style="padding-bottom: 2px;"> </td> <td style="border-bottom: black 2px solid; text-align: left;"> </td> <td style="border-bottom: black 2px solid; text-align: right;">4.96</td> <td style="text-align: left; padding-bottom: 2px;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 8.65pt;">Outstanding as of June 30, 2017</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">10,773,443</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">3.06</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;"> </td> <td> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="border-bottom: black 2px solid; text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: transparent; vertical-align: bottom;"> <td style="padding-bottom: 4px; text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable as of June 30, 2017</td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;"> </td> <td style="border-bottom: black 4px double; text-align: right;">6,484,316</td> <td style="text-align: left; padding-bottom: 4px;"> </td> <td style="padding-bottom: 4px;"> </td> <td style="border-bottom: black 4px double; text-align: left;">$</td> <td style="border-bottom: black 4px double; text-align: right;">4.16</td> <td style="text-align: left; padding-bottom: 4px;"> </td> </tr> </table> <div> </div>

<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 100%; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Shares</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted-<br />Average<br />Exercise Price</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Weighted-<br />Average<br />Remaining<br />Contractual<br />Term (in years)</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 2px; border-bottom-style: solid;" colspan="2" nowrap="nowrap">Aggregate<br />Intrinsic<br />Value</td> <td style="padding-bottom: 2px; font-weight: bold;"> </td> </tr> <tr style="vertical-align: bottom; background-color: transparent;"> <td style="width: 615.46px; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt;">Vested and unvested expected to vest at June 30, 2017</td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 189px; text-align: right;">10,566,460</td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 16px;"> </td> <td style="width: 16px; text-align: left;">$</td> <td style="width: 189px; text-align: right;">3.06</td> <td style="width: 16px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 188px; text-align: right;">6.2</td> <td style="width: 15px; text-align: left;"> </td> <td style="width: 15px;"> </td> <td style="width: 15px; text-align: left;">$</td> <td style="width: 188px; text-align: right;">479</td> <td style="width: 15px; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-indent: -8.65pt; padding-left: 8.65pt;">Exercisable at June 30, 2017</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">6,484,316</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">4.16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4.3</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;">$</td> <td style="text-align: right;">37</td> <td style="text-align: left;"> </td> </tr> </table>

15000000

108800000 68800000

15857000

14115000

7000

5000

7000

15859000

14108000

12923000

14176000

28782000

12923000

15859000

28284000

14176000

14108000

710000

988000

1856000

1109000

5461000 4455000

363000

413000

310000

296000

9189198

10773443

354330

421000

109000

312000

1015000

299000

716000

286000

74000

212000

829000

204000

625000

8715048

10773443

2537500

479105

6484316

3.71

3.06

1.19

4.96

4.16

10566460

3.06

P6Y2M12D

479000

6484316

4.16

P4Y3M18D

37000

600000

260000

300000

270000

1.10

0.72

2700000

P3Y3M18D

325149

153956

P4Y3M18D

8027900

3567956

15200000

2.50

1667000

5000000

3333000

15000000

30 day U.S. LIBOR

0.0065

0.0685

0.0808

P18M

P36M 0.06 We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.

75000000

0.05

354330

1.27

P10Y

382781000

202137000

27779000

15080000

929000

more than 50 percentage points P3Y

37000

496000

EX-101.SCH 6 arql-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED BALANCE SHEETS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - COLLABORATIONS AND ALLIANCES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - NET LOSS PER SHARE link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - STOCK OFFERING link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - LOAN AGREEMENT link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - LOAN AGREEMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - NET LOSS PER SHARE (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - STOCK OFFERING (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - LOAN AGREEMENT (Details) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - LOAN AGREEMENT (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - INCOME TAXES (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 arql-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 arql-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 arql-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash and Cash Equivalents, at Carrying Value Cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Marketable Securities, Current Marketable securities-short term Marketable securities-short term Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Net property and equipment Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Other Assets, Noncurrent Other assets Total other assets Assets Total assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Accounts payable and accrued expenses, Total Liabilities, Current Total current liabilities Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Notes Payable, Noncurrent Notes payable Liabilities Total liabilities Total liabilities Commitments and Contingencies Commitment and contingencies Stockholders Equity Attributable To Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding Common Stock, Value, Issued Common stock, $0.01 par value; 100,000,000 shares authorized; 71,171,551 and 71,146,209 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively Additional Paid In Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Accumulated Other Comprehensive Income (Loss), Net Of Tax Accumulated other comprehensive income (loss) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Accumulated deficit Stockholders' Equity Attributable To Parent Balance Total stockholders' equity Balance Balance Liabilities and Equity Total liabilities and stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Balance (in shares) Balance (in shares) Income Statement [Abstract] Income Statement [Abstract] Revenues [Abstract] Revenue: Research and Development Revenue Net revenues Research and development revenue Aggregate revenue during the period from research and development agreements. Costs and Expenses [Abstract] Costs and expenses: Research and Development Expense Research and development Research and development General and Administrative Expense General and administrative General and administrative Costs and Expenses Total costs and expenses Total costs and expenses Operating Income (Loss) Loss from operations Loss from operations Investment Income, Interest Interest income Interest Expense Interest expense Interest expense Net Income (Loss) Attributable To Parent Net income (loss) Net loss Net loss Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain (loss) on marketable securities Comprehensive Income (Loss), Net Of Tax, Attributable To Parent Comprehensive loss Comprehensive loss Earnings Per Share, Basic and Diluted [Abstract] Basic and diluted net loss per share: Earnings Per Share, Basic and Diluted Net earnings (loss) per share Net loss per share (in dollars per share) Net loss per share Net loss per share Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average basic and diluted common shares outstanding (in shares) Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities, Continuing Operations [Abstract] Cash flows from operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization Depreciation and amortization expense Depreciation and amortization Depreciation and amortization Accretion (Amortization) Of Discounts and Premiums, Investments Amortization of premium/discount on marketable securities Amortization of premium (discount) on marketable securities Amortization of Debt Discount (Premium) Amortization of debt discount Amortization of debt discount Share-Based Compensation Share-based compensation expense related to restricted stock Non-cash stock compensation Non-cash stock compensation Increase (Decrease) In Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) In Prepaid Expense and Other Assets Prepaid expenses and other current assets Prepaid expenses and other current assets Prepaid expenses and other assets Increase (Decrease) In Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Accounts payable and accrued expenses Increase (Decrease) In Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net use of cash Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities, Continuing Operations [Abstract] Cash flows from investing activities: Payments To Acquire Marketable Securities Purchases of marketable securities Purchases of marketable securities Purchases of marketable securities Proceeds From Sale and Maturity Of Marketable Securities Proceeds from sale or maturity of marketable securities Proceeds from sale or maturity of marketable securities Payments to Acquire Property, Plant, and Equipment Additions to property and equipment2 Additions to property and equipment Net Cash Provided By (Used In) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Cash flows from financing activities: Proceeds from Notes Payable Proceeds from notes payable and warrants, net Proceeds from Issuance Initial Public Offering Proceeds from stock offering, net Proceeds from Stock Options Exercised Additional proceeds if options exercised Proceeds from employee stock option exercises and employee stock purchase plan purchases Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash flows from financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Net increase in cash and cash equivalents Organization and Nature Of Operations [Abstract] Organization and Nature Of Operations [Abstract] Business Description and Basis of Presentation [Text Block] NATURE OF OPERATIONS AND BASIS OF PRESENTATION Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement Disclosure [Text Block] COLLABORATIONS AND ALLIANCES Marketable Securities and Fair Value Measurements [Abstract] Marketable Securities and Fair Value Measurements [Abstract] Financial Instruments Disclosure [Text Block] MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] ACCOUNTS PAYABLE AND ACCRUED EXPENSES Earnings Per Share [Abstract] Loss per share: Earnings Per Share [Text Block] NET LOSS PER SHARE Compensation and Retirement Disclosure [Abstract] Compensation and Retirement Disclosure [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] STOCK-BASED COMPENSATION AND STOCK PLANS Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] STOCK OFFERING Long-term Debt, Unclassified [Abstract] Long-term Debt [Text Block] LOAN AGREEMENT New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements and Changes in Accounting Principles [Text Block] RECENT ACCOUNTING PRONOUNCEMENTS Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES Available-For-Sale Securities [Table Text Block] Schedule of fair value of available-for-sale marketable securities Fair Value, Assets Measured On Recurring Basis [Table Text Block] Schedule of assets measured at fair value on a recurring basis Schedule Of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of accounts payable and accrued expense Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of stock-based compensation expense Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of activity of options under stock plans Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable [Table Text Block] Schedule of shares vested, expected to vest and exercisable Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of expected remaining loan repayment Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others [Line Items] Research and Development Arrangement, Contract to Perform for Others [Line Items] Loan agreement face amount Loan principal amount Schedule Of Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Type Of Arrangement and Non-Arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-Arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Daiichi Sankyo Tivantinib Agreement [Member] Daiichi Sankyo Tivantinib Agreement Contractual agreement of the company. Kyowa Hakko Kirin Licensing Agreement [Member] Kyowa Hakko Kirin Licensing Agreement Contractual agreement of the company. Products and Services [Axis] Products and Services [Domain] Phase 3 Collaboration Costs [Member] Phase 3 collaboration costs Represents information about Phase 3 collaboration costs. Collaborative Arrangements and Non-Collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Cumulative Phase Costs Attributable To Collaboration Agreements Cumulative share of phase 3 collaboration costs The amount of cumulative share of costs since inception. Cumulative Phase Costs Attributable To Collaboration Agreements In Excess Of Milestone Payments and Royalties Cumulative share of phase 3 collaboration costs in excess of milestones amounts received The amount received in excess. Schedule Of Available-For-Sale Securities [Table] Schedule of Available-for-sale Securities [Table] Debt Security [Axis] Debt Security [Axis] Major Types Of Debt Securities [Domain] Major Types of Debt Securities [Domain] Corporate Debt Securities [Member] Corporate debt securities Corporate debt securities-short term & long term Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Current [Member] Short term Financial instruments current member. Schedule Of Available-For-Sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Available-For-Sale Securities, Amortized Cost Basis Amortized Cost Amortized Cost Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Gains Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Gross Unrealized Losses Gross Unrealized Losses Available-for-sale Securities Fair Value Corporate debt securities-short term Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 2 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 Major Types Of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types Of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Fair Value, Assets and Liabilities Measured On Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents Assets, Fair Value Disclosure Total Accounts Payable, Current Accounts payable Accrued Payroll Taxes, Current Accrued payroll Accrued Outsourced Preclinical and Clinical Fees Current Accrued outsourced pre-clinical and clinical fees Carrying value as of the balance sheet date of obligations incurred and payable for accrued outsourced pre clinical and clinical fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Professional Fees, Current Accrued professional fees Other Accrued Liabilities, Current Other accrued expenses Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Potential common shares issued upon exercise of outstanding stock options Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Share issued upon the exercise of outstanding employee stock warrant Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Research and Development Expense [Member] Research and development General and Administrative Expense [Member] General and administrative Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Line Items] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Allocated Share-Based Compensation Expense Total stock-based compensation expense Share-based compensation expense Stock-based compensation expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Award Type [Domain] Employee Stock Option [Member] Stock Options Performance-based stock options Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding [Roll Forward] Number of Shares Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Number of Options Outstanding at December 31, 2013 Outstanding as of December 31, 2011 Outstanding as of December 31, 2016 Outstanding as of June 30, 2017 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross Employment agreement to grant CEO stock option Granted Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Number of the non-vested options shares , Forfeited during the period Cancelled Cancelled Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Options Exercisable as of December 31, 2013 Exercisable as of June 30, 2017 Number of shares currently exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted Average Exercise Price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options Outstanding, Weighted Average Exercise Price Outstanding as of December 31, 2011 Outstanding as of December 31, 2016 Outstanding as of June 30, 2017 Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise price of the options non vested which are forfeited during the period Cancelled Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options Exercisable, Weighted Average Exercise Price Exercisable as of June 30, 2017 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Vested and unvested expected to vest shares Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Exercise Price Vested and unvested expected to vest, weighted-average exercise price Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Vested and unvested expected to vest, weighted-average remaining contractual term (in years) Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Aggregate Intrinsic Value Vested and unvested expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable, Number Exercisable shares Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Exercisable, Weighted Average Exercise Price Exercisable, weighted-average exercise price EX-101.PRE 10 arql-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Jul. 20, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ARQULE INC
Entity Central Index Key	0001019695
Trading Symbol	arql
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		71,171,551
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 16,899	$ 15,267
Marketable securities-short term	14,108	15,859
Prepaid expenses and other current assets	421	822
Total current assets	31,428	31,948
Property and equipment, net	142	180
Other assets	204	252
Total assets	31,774	32,380
Current liabilities:
Accounts payable and accrued expenses	7,261	8,700
Total current liabilities	7,261	8,700
Long-term liabilities:
Notes payable	14,427
Total liabilities	21,688	8,700
Commitment and contingencies
Preferred stock, $0.01 par value; 1,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized; 71,171,551 and 71,146,209 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively	711	711
Additional paid-in capital	528,994	527,802
Accumulated other comprehensive income (loss)	(7)	2
Accumulated deficit	(519,612)	(504,835)
Total stockholders' equity	10,086	23,680
Total liabilities and stockholders' equity	$ 31,774	$ 32,380

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	71,171,551	71,146,209
Common stock, shares outstanding	71,171,551	71,146,209

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Research and development revenue		$ 1,072		$ 2,299
Costs and expenses:
Research and development	$ 4,983	4,337	$ 10,177	8,535
General and administrative	1,866	1,887	3,940	3,931
Total costs and expenses	6,849	6,224	14,117	12,466
Loss from operations	(6,849)	(5,152)	(14,117)	(10,167)
Interest income	37	52	59	86
Interest expense	(389)		(719)
Net loss	(7,201)	(5,100)	(14,777)	(10,081)
Unrealized gain (loss) on marketable securities	(5)		(9)	29
Comprehensive loss	$ (7,206)	$ (5,100)	$ (14,786)	$ (10,052)
Basic and diluted net loss per share:
Net loss per share (in dollars per share)	$ (0.10)	$ (0.07)	$ (0.21)	$ (0.15)
Weighted average basic and diluted common shares outstanding (in shares)	71,149	71,062	71,143	68,275

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (14,777)	$ (10,081)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	38	53
Amortization of premium (discount) on marketable securities	(9)	40
Amortization of debt discount	150
Non-cash stock compensation	828	1,015
Changes in operating assets and liabilities:
Prepaid expenses and other assets	449	294
Accounts payable and accrued expenses	(1,439)	1
Deferred revenue		(2,290)
Net cash used in operating activities	(14,760)	(10,968)
Cash flows from investing activities:
Purchases of marketable securities	(14,076)	(21,648)
Proceeds from sale or maturity of marketable securities	15,827	20,765
Additions to property and equipment		(15)
Net cash provided by (used in) investing activities	1,751	(898)
Cash flows from financing activities:
Proceeds from notes payable and warrants, net	14,624
Proceeds from stock offering, net		15,174
Proceeds from employee stock option exercises and employee stock purchase plan purchases	17	163
Net cash provided by financing activities	14,641	15,337
Net increase in cash and cash equivalents	1,632	3,471
Cash and cash equivalents, beginning of period	15,267	13,983
Cash and cash equivalents, end of period	$ 16,899	$ 17,454

XML 16 R6.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

6 Months Ended

Jun. 30, 2017

Organization and Nature Of Operations [Abstract]

NATURE OF OPERATIONS AND BASIS OF PRESENTATION

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

•

ARQ 751, a next-generation inhibitor of AKT, in Phase 1 for solid tumors harboring the AKT1 or PI3K mutation;

•

XML 17 R7.htm IDEA: XBRL DOCUMENT

COLLABORATIONS AND ALLIANCES

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

COLLABORATIONS AND ALLIANCES

2. COLLABORATIONS AND ALLIANCES

Daiichi Sankyo Tivantinib Agreement

Kyowa Hakko Kirin Licensing Agreement

XML 18 R8.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

6 Months Ended

Jun. 30, 2017

Marketable Securities and Fair Value Measurements [Abstract]

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

3. MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS

The following is a summary of the fair value of available-for-sale marketable securities we held at June 30, 2017 and

December 31, 2016:

June 30, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	14,115	$	-	$	(7	)	$	14,108
Total available-for-sale marketable securities	$	14,115	$	-	$	(7	)	$	14,108

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	15,857	$	7	$	(5	)	$	15,859
Total available-for-sale marketable securities	$	15,857	$	7	$	(5	)	$	15,859

Our available-for-sale marketable securities in a loss position at June 30, 2017, and December 31, 2016 were in a continuous unrealized loss position for less than 12 months.

	June 30, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	14,176	$	14,176	$	—	$	—
Corporate debt securities-short term		14,108		—		14,108		—
Total	$	28,284	$	14,176	$	14,108	$	—

	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	12,923	$	12,923	$	—	$	—
Corporate debt securities-short term		15,859		—		15,859		—
Total	$	28,782	$	12,923	$	15,859	$	—

XML 19 R9.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

4. ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses include the following at June 30, 2017 and December 31, 2016:

	June 30, 2017		December 31, 2016
Accounts payable	$	988	$	710
Accrued payroll		1,109		1,856
Accrued outsourced pre-clinical and clinical fees		4,455		5,461
Accrued professional fees		413		363
Other accrued expenses		296		310
	$	7,261	$	8,700

XML 20 R10.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE

6 Months Ended

Jun. 30, 2017

Earnings Per Share [Abstract]

NET LOSS PER SHARE

5. NET LOSS PER SHARE

XML 21 R11.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS

6 Months Ended

Jun. 30, 2017

Compensation and Retirement Disclosure [Abstract]

STOCK-BASED COMPENSATION AND STOCK PLANS

6. STOCK-BASED COMPENSATION AND STOCK PLANS

The following table presents stock-based compensation expense included in our Condensed Statements of Operations and Comprehensive Loss:

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development	$	74	$	109	$	204	$	299
General and administrative		212		312		625		716
Total stock-based compensation expense	$	286	$	421	$	829	$	1,015

Option activity under our stock plans for the six months ended June 30, 2017 was as follows:

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016		8,715,048		$	3.71
Granted		2,537,500			1.19
Exercised		—			—
Cancelled		(479,105	)		4.96
Outstanding as of June 30, 2017		10,773,443		$	3.06

Exercisable as of June 30, 2017		6,484,316		$	4.16

Shares vested, expected to vest and exercisable at June 30, 2017 are as follows:

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at June 30, 2017		10,566,460	$	3.06		6.2	$	479
Exercisable at June 30, 2017		6,484,316	$	4.16		4.3	$	37

XML 22 R12.htm IDEA: XBRL DOCUMENT

STOCK OFFERING

6 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

STOCK OFFERING

7. STOCK OFFERING

XML 23 R13.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT

6 Months Ended

Jun. 30, 2017

Long-term Debt, Unclassified [Abstract]

LOAN AGREEMENT

8. LOAN AGREEMENT

The expected remaining repayment of the $15 million loan principal is as follows:

2018	$	1,667
2019		5,000
2020		5,000
2021		3,333
	$	15,000

We paid the Lender an upfront facility fee of $75,000.

XML 24 R14.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

6 Months Ended

Jun. 30, 2017

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

9. RECENT ACCOUNTING PRONOUNCEMENTS

XML 25 R15.htm IDEA: XBRL DOCUMENT

INCOME TAXES

6 Months Ended

Jun. 30, 2017

Income Tax Disclosure [Abstract]

INCOME TAXES

10. INCOME TAXES

XML 26 R16.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)

6 Months Ended

Jun. 30, 2017

Marketable Securities and Fair Value Measurements [Abstract]

Schedule of fair value of available-for-sale marketable securities

June 30, 2017	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	14,115	$	-	$	(7	)	$	14,108
Total available-for-sale marketable securities	$	14,115	$	-	$	(7	)	$	14,108

December 31, 2016	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Security type
Corporate debt securities-short term	$	15,857	$	7	$	(5	)	$	15,859
Total available-for-sale marketable securities	$	15,857	$	7	$	(5	)	$	15,859

Schedule of assets measured at fair value on a recurring basis

	June 30, 2017		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	14,176	$	14,176	$	—	$	—
Corporate debt securities-short term		14,108		—		14,108		—
Total	$	28,284	$	14,176	$	14,108	$	—

	December 31, 2016		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash equivalents	$	12,923	$	12,923	$	—	$	—
Corporate debt securities-short term		15,859		—		15,859		—
Total	$	28,782	$	12,923	$	15,859	$	—

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

6 Months Ended

Jun. 30, 2017

Payables and Accruals [Abstract]

Schedule of accounts payable and accrued expense

	June 30, 2017		December 31, 2016
Accounts payable	$	988	$	710
Accrued payroll		1,109		1,856
Accrued outsourced pre-clinical and clinical fees		4,455		5,461
Accrued professional fees		413		363
Other accrued expenses		296		310
	$	7,261	$	8,700

XML 28 R18.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Tables)

6 Months Ended

Jun. 30, 2017

Compensation and Retirement Disclosure [Abstract]

Schedule of stock-based compensation expense

	Three Months Ended June 30,				Six Months Ended June 30,
	2017		2016		2017		2016
Research and development	$	74	$	109	$	204	$	299
General and administrative		212		312		625		716
Total stock-based compensation expense	$	286	$	421	$	829	$	1,015

Schedule of activity of options under stock plans

Stock Options	Number of Shares			Weighted Average Exercise Price
Outstanding as of December 31, 2016		8,715,048		$	3.71
Granted		2,537,500			1.19
Exercised		—			—
Cancelled		(479,105	)		4.96
Outstanding as of June 30, 2017		10,773,443		$	3.06

Exercisable as of June 30, 2017		6,484,316		$	4.16

Schedule of shares vested, expected to vest and exercisable

	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Vested and unvested expected to vest at June 30, 2017		10,566,460	$	3.06		6.2	$	479
Exercisable at June 30, 2017		6,484,316	$	4.16		4.3	$	37

XML 29 R19.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT (Tables)

6 Months Ended

Jun. 30, 2017

Long-term Debt, Unclassified [Abstract]

Schedule of expected remaining loan repayment

2018	$	1,667
2019		5,000
2020		5,000
2021		3,333
	$	15,000

XML 30 R20.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jan. 06, 2017
Organization and Nature Of Operations [Abstract]
Net use of cash	$ (14,760)	$ (10,968)
Loan principal amount			$ 15,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

COLLABORATIONS AND ALLIANCES (Detail Textuals) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenues		$ 1,072		$ 2,299
Daiichi Sankyo Tivantinib Agreement \| Phase 3 collaboration costs
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cumulative share of phase 3 collaboration costs			$ 108,800
Cumulative share of phase 3 collaboration costs in excess of milestones amounts received			68,800
Net revenues	$ 0	600	0	1,400
Kyowa Hakko Kirin Licensing Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Net revenues	$ 0	$ 500	$ 0	$ 900

XML 32 R22.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 14,115	$ 15,857
Gross Unrealized Gains		7
Gross Unrealized Losses	(7)	(5)
Fair Value	14,108	15,859
Corporate debt securities \| Short term
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	14,115	15,857
Gross Unrealized Gains		7
Gross Unrealized Losses	(7)	(5)
Fair Value	$ 14,108	$ 15,859

XML 33 R23.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term	$ 14,108	$ 15,859
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	14,176	12,923
Total	28,284	28,782
Fair Value, Measurements, Recurring \| Corporate debt securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term	14,108	15,859
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	14,176	12,923
Total	14,176	12,923
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets (Level 1) \| Corporate debt securities \| Short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total	14,108	15,859
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Corporate debt securities \| Short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term	14,108	15,859
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| Corporate debt securities \| Short term
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Corporate debt securities-short term

XML 34 R24.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Payables and Accruals [Abstract]
Accounts payable	$ 988	$ 710
Accrued payroll	1,109	1,856
Accrued outsourced pre-clinical and clinical fees	4,455	5,461
Accrued professional fees	413	363
Other accrued expenses	296	310
Accounts payable and accrued expenses, Total	$ 7,261	$ 8,700

XML 35 R25.htm IDEA: XBRL DOCUMENT

NET LOSS PER SHARE (Detail Textuals) - shares	3 Months Ended		6 Months Ended
NET LOSS PER SHARE (Detail Textuals) - shares	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Earnings Per Share [Abstract]
Potential common shares issued upon exercise of outstanding stock options	10,773,443	9,189,198	10,773,443	9,189,198
Share issued upon the exercise of outstanding employee stock warrant			354,330

XML 36 R26.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 286	$ 421	$ 829	$ 1,015
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	74	109	204	299
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 212	$ 312	$ 625	$ 716

XML 37 R27.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) - Stock Options	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Number of Shares
Outstanding as of December 31, 2016 \| shares	8,715,048
Granted \| shares	2,537,500
Exercised \| shares
Cancelled \| shares	(479,105)
Outstanding as of June 30, 2017 \| shares	10,773,443
Exercisable as of June 30, 2017 \| shares	6,484,316
Weighted Average Exercise Price
Outstanding as of December 31, 2016 \| $ / shares	$ 3.71
Granted \| $ / shares	1.19
Exercised \| $ / shares
Cancelled \| $ / shares	4.96
Outstanding as of June 30, 2017 \| $ / shares	3.06
Exercisable as of June 30, 2017 \| $ / shares	$ 4.16

XML 38 R28.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) - Stock Options $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested and unvested expected to vest shares \| shares	10,566,460
Vested and unvested expected to vest, weighted-average exercise price \| $ / shares	$ 3.06
Vested and unvested expected to vest, weighted-average remaining contractual term (in years)	6 years 2 months 12 days
Vested and unvested expected to vest, aggregate intrinsic value \| $	$ 479
Exercisable shares \| shares	6,484,316
Exercisable, weighted-average exercise price \| $ / shares	$ 4.16
Exercisable, weighted-average remaining contractual term (in years)	4 years 3 months 18 days
Exercisable, aggregate intrinsic value \| $	$ 37

XML 39 R29.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals)	1 Months Ended
	Apr. 30, 2017 shares
Performance-based stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	270,000
Performance-based stock options \| Chief Executive Officer Employment Agreement \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested during the period	600,000
Performance-based stock options \| Chief Medical Officer Employment Agreement \| Chief Medical Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested during the period	260,000
Performance-based stock units \| Chief Operating Officer Employment Agreement \| Chief Operating Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares vested during the period	300,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value of options outstanding	$ 496	$ 496
Intrinsic value of options exercisable	37	$ 37
Weighted average grant date fair value of options granted (in dollars per share)		$ 0.72	$ 1.10
Compensation cost not yet recognized related to non-vested option awards	$ 2,700	$ 2,700
Weighted-average recognition period related to non-vested option awards		3 years 3 months 18 days
Number of shares expired during the period	325,149
Number of shares forfeited during the period	153,956
Weighted average remaining contractual life for options exercisable	4 years 3 months 18 days

XML 41 R31.htm IDEA: XBRL DOCUMENT

STOCK OFFERING (Detail Textuals) - Definitive stock purchase agreements $ / shares in Units, $ in Millions	1 Months Ended
	Feb. 26, 2016 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock issued under agreement	8,027,900
Number of non transferable options issued	3,567,956
Aggregate net proceeds \| $	$ 15.2
Stock option exercise price (in dollars per share) \| $ / shares	$ 2.50

XML 42 R32.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT (Details) $ in Thousands	Jan. 06, 2017 USD ($)
Long-term Debt, Unclassified [Abstract]
2018	$ 1,667
2019	5,000
2020	5,000
2021	3,333
Long-term Debt, Fair Value	$ 15,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

LOAN AGREEMENT (Detail Textuals) - USD ($) $ / shares in Units, $ in Thousands	Jan. 06, 2017	Jun. 30, 2017
Long-term Debt, Unclassified [Abstract]
Loan agreement face amount	$ 15,000
Debt Instrument description	30 day U.S. LIBOR
Percentage of interest rate basis	0.65%
Percentage of interest rate during the period	6.85%
Percentage of interest rate end of the period		8.08%
Interest only-payment duration	18 months
Debt amortization period	36 months
Expected remaining repayment	$ 15,000
Percentage of principal amount of loan for final payment	6.00%
Prepayment amount description	We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee also is paid equal to (i) 3% of the outstanding principal balance if prepayment occurs in months 1-12 following the closing, (ii) 2.0% of the outstanding principal balance in months 13-24 following the closing, and (iii) 1% thereafter.
Lender upfront facility fee	$ 75,000
Percentage debt instrument default interest rate	5.00%
Number of warrants issued to purchase common stock	354,330
Exercise price of warrants or rights	$ 1.27
Term of warrant	10 years

XML 44 R34.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Detail Textuals) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
INCOME TAXES (Detail Textuals) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Increase in ownership percentage of certain stockholders or public groups	more than 50 percentage points
Ownership change, increase in ownership percentage, term	3 years
Federal income tax
Operating Loss Carryforwards [Line Items]
Net operating loss		$ 382,781
Net operating loss generated from excess tax deduction from share based awards		15,080
State income tax
Operating Loss Carryforwards [Line Items]
Net operating loss		202,137
Net operating loss generated from excess tax deduction from share based awards		929
Research and development credit carryforwards
Operating Loss Carryforwards [Line Items]
Net operating loss		$ 27,779

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 60 155 1 false 24 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://www.arqule.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONDENSED BALANCE SHEETS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDBALANCESHEETSUnaudited CONDENSED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 003 - Statement - CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) Sheet http://www.arqule.com/role/CONDENSEDBALANCESHEETSUnauditedParentheticals CONDENSED BALANCE SHEETS (Unaudited) (Parentheticals) Statements 3 false false R4.htm 004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.arqule.com/role/CONDENSEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 6 false false R7.htm 007 - Disclosure - COLLABORATIONS AND ALLIANCES Sheet http://www.arqule.com/role/COLLABORATIONSANDALLIANCES COLLABORATIONS AND ALLIANCES Notes 7 false false R8.htm 008 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS Notes 8 false false R9.htm 009 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES ACCOUNTS PAYABLE AND ACCRUED EXPENSES Notes 9 false false R10.htm 010 - Disclosure - NET LOSS PER SHARE Sheet http://www.arqule.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 10 false false R11.htm 011 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANS STOCK-BASED COMPENSATION AND STOCK PLANS Notes 11 false false R12.htm 012 - Disclosure - STOCK OFFERING Sheet http://www.arqule.com/role/StockOffering STOCK OFFERING Notes 12 false false R13.htm 013 - Disclosure - LOAN AGREEMENT Sheet http://www.arqule.com/role/LoanAgreement LOAN AGREEMENT Notes 13 false false R14.htm 014 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS Sheet http://www.arqule.com/role/RECENTACCOUNTINGPRONOUNCEMENTS RECENT ACCOUNTING PRONOUNCEMENTS Notes 14 false false R15.htm 015 - Disclosure - INCOME TAXES Sheet http://www.arqule.com/role/INCOMETAXES INCOME TAXES Notes 15 false false R16.htm 016 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS 16 false false R17.htm 017 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESTables ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables) Tables http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSES 17 false false R18.htm 018 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables STOCK-BASED COMPENSATION AND STOCK PLANS (Tables) Tables http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANS 18 false false R19.htm 019 - Disclosure - LOAN AGREEMENT (Tables) Sheet http://www.arqule.com/role/LOANAGREEMENTTables LOAN AGREEMENT (Tables) Tables http://www.arqule.com/role/LoanAgreement 19 false false R20.htm 020 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) Sheet http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATIONDetailTextuals NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Detail Textuals) Details http://www.arqule.com/role/NATUREOFOPERATIONSANDBASISOFPRESENTATION 20 false false R21.htm 021 - Disclosure - COLLABORATIONS AND ALLIANCES (Detail Textuals) Sheet http://www.arqule.com/role/CollaborationsAndAlliancesDetailTextuals COLLABORATIONS AND ALLIANCES (Detail Textuals) Details http://www.arqule.com/role/COLLABORATIONSANDALLIANCES 21 false false R22.htm 022 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Sheet http://www.arqule.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryOfFairValueOfAvailableForSaleSecuritiesDetails MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of fair value of available-for-sale securities (Details) Details 22 false false R23.htm 023 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) Sheet http://www.arqule.com/role/Marketablesecuritiesandfairvaluemeasurementsassetsmeasuredatfairvalueonrecurringbasisdetails1 MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Assets measured at fair value on a recurring basis (Details 1) Details 23 false false R24.htm 024 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Sheet http://www.arqule.com/role/ACCOUNTSPAYABLEANDACCRUEDEXPENSESSummaryOfAccountsPayableAndAccruedExpensesDetails ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of accounts payable and accrued expenses (Details) Details 24 false false R25.htm 025 - Disclosure - NET LOSS PER SHARE (Detail Textuals) Sheet http://www.arqule.com/role/NETLOSSPERSHAREDetailTextuals NET LOSS PER SHARE (Detail Textuals) Details http://www.arqule.com/role/NETLOSSPERSHARE 25 false false R26.htm 026 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSStockBasedCompensationExpenseDetails STOCK-BASED COMPENSATION AND STOCK PLANS - Stock-based compensation expense (Details) Details 26 false false R27.htm 027 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSOptionActivityDetails1 STOCK-BASED COMPENSATION AND STOCK PLANS - Option activity (Details 1) Details 27 false false R28.htm 028 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) Sheet http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSSharesVestedExpectedToVestAndExercisableDetails2 STOCK-BASED COMPENSATION AND STOCK PLANS - Shares vested, expected to vest and exercisable (Details 2) Details 28 false false R29.htm 029 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) Sheet http://www.arqule.com/role/StockBasedCompensationAndStockPlansDetailsTextuals STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 29 false false R30.htm 030 - Disclosure - STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) Sheet http://www.arqule.com/role/StockBasedCompensationAndStockPlansDetailTextuals1 STOCK-BASED COMPENSATION AND STOCK PLANS (Detail Textuals 1) Details http://www.arqule.com/role/STOCKBASEDCOMPENSATIONANDSTOCKPLANSTables 30 false false R31.htm 031 - Disclosure - STOCK OFFERING (Detail Textuals) Sheet http://www.arqule.com/role/STOCKOFFERINGDetailTextuals STOCK OFFERING (Detail Textuals) Details http://www.arqule.com/role/StockOffering 31 false false R32.htm 032 - Disclosure - LOAN AGREEMENT (Details) Sheet http://www.arqule.com/role/LOANAGREEMENTDetails LOAN AGREEMENT (Details) Details http://www.arqule.com/role/LOANAGREEMENTTables 32 false false R33.htm 033 - Disclosure - LOAN AGREEMENT (Detail Textuals) Sheet http://www.arqule.com/role/LoanAgreementDetailsTextuals LOAN AGREEMENT (Detail Textuals) Details http://www.arqule.com/role/LOANAGREEMENTTables 33 false false R34.htm 034 - Disclosure - INCOME TAXES (Detail Textuals) Sheet http://www.arqule.com/role/INCOMETAXESDetailTextuals INCOME TAXES (Detail Textuals) Details http://www.arqule.com/role/INCOMETAXES 34 false false All Reports Book All Reports arql-20170630.xml arql-20170630.xsd arql-20170630_cal.xml arql-20170630_def.xml arql-20170630_lab.xml arql-20170630_pre.xml true true ZIP 51 0001571049-17-007240-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001571049-17-007240-xbrl.zip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end